Plain-English translation of NCT05570253 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called combined with (a chemotherapy drug) to treat advanced triple-negative breast cancer. Some patients will receive the new medication plus chemotherapy, while others will receive chemotherapy alone, so doctors can compare how well the treatment works and whether it's safe.
Triple-negative breast cancer is difficult to treat because it doesn't respond to hormone therapies that help other types of breast cancer. This study explores whether this medication can help make chemotherapy more effective, especially for patients who also have metabolic problems like diabetes or obesity.
You likely qualify if…
You likely don't qualify if…
You will first visit the research team for screening tests and blood work to make sure you are healthy enough to participate. Then you'll begin treatment—either the new medication plus chemotherapy, or chemotherapy alone—and return regularly for check-up visits and scans to see how well the treatment is working and to monitor for side effects. The study involves 15 patients in a safety phase first, followed by 40 more patients who are randomly assigned to one of the two treatment groups.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States